Send to

Choose Destination
See comment in PubMed Commons below
Urol Clin North Am. 1997 May;24(2):407-14.

Prostate-specific antigen after radiation therapy. Prognosis by pretreatment level and post-treatment nadir.

Author information

Department of Urology, Virginia Prostate Center, Eastern Virginia Medical School, Norfolk, USA.


After external beam radiation therapy, pretreatment prostate-specific antigen (PSA) is the most powerful predictor of outcome as measured PSA (biochemical) failure. The post-treatment nadir levels of PSA that predict best for subsequent freedom from PSA failure are debatable, and many nadir levels have been proposed as targets. Although lower nadirs generally are associated with superior outcomes, the identification of a single absolute nadir level was not selected at a recent ASTRO consensus conference. Rather, three consecutive PSA rises above the nadir, with date of failure at the midpoint between the nadir and first rise, were selected as a more useful end point for treatment failure.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center